TScan Therapeutics EBITDA per Share

What does TScan Therapeutics do? TScan Therapeutics, Inc. develops TCR-T therapies for liquid cancers and solid tumors, focusing on TSC-100 and TSC-101 for hematologic malignancies post-transplant. The company builds its ImmunoBank with solid tumor targets across HLA types and advances six solid tumor programs including TSC-204 in Phase I and TSC-200/TSC-203 in IND-enabling activities. TScan generates revenue through clinical development partnerships and future product sales of its TCR-T therapies. Its primary customers are healthcare providers and patients seeking advanced cancer treatments. The company targets the oncology segment with a focus on hematologic malignancies and solid tumors, leveraging its ImmunoBank to expand therapeutic options. TScan Therapeutics, Inc. is developing TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 in clinical development for hematologic malignancies. The firm’s ImmunoBank collects solid tumor targets across HLA types to support multiplexed TCR-T therapies. TScan advances six solid tumor programs, including TSC-204 entering Phase I and TSC-200/TSC-203 in IND-enabling stages. Revenue comes from partnerships with biopharmaceutical companies for clinical development and eventual sales of TCR-T therapies. The target market includes oncology specialists and cancer patients requiring novel treatments for residual disease and relapse prevention. The company’s pipeline includes TSC-100 and TSC-101 for hematologic malignancies after transplantation and TSC-204 to TSC-205 for solid tumors. TScan’s ImmunoBank enables multiplexed TCR-T therapies targeting various solid tumors. Revenue streams are derived from clinical development collaborations and future commercialization of its therapies. Key segments are oncology providers treating hematologic malignancies and solid tumors, with a focus on post-transplant residual disease management and relapse prevention. TScan Therapeutics is one of the most popular companies on Eulerpool.